Bio Pharma Dive
OCTOBER 20, 2021
Anticipating regulatory clearance of the pill, the group aims to speed access by investing in the manufacturing of generic versions of the drug.
XTalks
OCTOBER 20, 2021
Despite major accomplishments in the plant-based dairy space over the last few years, the animal-based dairy sector is proving there is still room for innovation. Taking notes from the VegTech sector , the dairy industry is diversifying to meet personal and planetary health targets, prioritizing nutrition and sustainability, along with flavor and accessibility. .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
OCTOBER 20, 2021
The agency also cleared booster shots of all three currently available vaccines to be used interchangeably, a so-called mix-and-match approach that recent study results showed could boost immune responses.
XTalks
OCTOBER 20, 2021
Barry Callebaut, a manufacturer of high-quality chocolate and cocoa products, is introducing a nutraceutical fruit drink made with the cacaofruit itself, called Elix. The new beverage has a zesty, fruity flavor that claims to promote circulatory health. In addition, the company created a product that keeps all the nutrients of the cacaofruit intact in order to provide the consumer with a nutraceutical beverage.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Bio Pharma Dive
OCTOBER 20, 2021
Sales of Aduhelm during the third quarter totaled only $300,000, falling well below expectations amid controversy over its approval and physician reluctance to prescribe it.
BioSpace
OCTOBER 20, 2021
Novavax is having problems getting its COVID-19 vaccine to the finish line. Shares plunged more than 23% in premarket trading today after reports that it is having manufacturing problems.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma in Brief
OCTOBER 20, 2021
SUMMARY. The Federal Court has granted Merck Canada Inc.’s ( Merck ) application for judicial review of a decision of the Minister of Health ( Minister ) denying a Certificate of Supplementary Protection ( CSP ) for Canadian Patent No. 2,670,892 ( 892 Patent ) and the drug BELSOMRA (suvorexant). BACKGROUND. A CSP provides patent-like rights and is intended to compensate patentees for a period of patent term lost while innovative pharmaceutical products undergo research and regulatory approval. [
BioSpace
OCTOBER 20, 2021
A subtype of the Delta variant might be rising, although it’s not yet clear if it’s more transmissible or lethal than the original Delta variant. Read on for that and more COVID-19 news.
Scienmag
OCTOBER 20, 2021
For five million years, woolly mammoths roamed the earth until they vanished for good nearly 4,000 years ago – and scientists have finally proved why. Credit: Daniel Eskridge For five million years, woolly mammoths roamed the earth until they vanished for good nearly 4,000 years ago – and scientists have finally proved why. The hairy […].
BioSpace
OCTOBER 20, 2021
An experimental AstraZeneca cancer drug trial has been placed on hold due to safety concerns. This news comes two years after Amgen was also forced to pause a study of a drug within the same class.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Scienmag
OCTOBER 20, 2021
A new study from the University of Southampton has demonstrated a new method to safely clean and reuse facemask respirators with advanced low-temperature plasma technology. The discovery could help future pandemic responses by providing contingency options should a shortage of personal protective equipment (PPE) for frontline healthcare staff occur again.
BioSpace
OCTOBER 20, 2021
?The entire lot of CUBICIN (daptomycin), numbered 934778, which has an expiry date of June 2022, will be recalled from the user level, including administering institutions and hospitals.
pharmaphorum
OCTOBER 20, 2021
Nicolas Vachicouras, CEO of Neurosoft Bioelectronics, tells us how Neurosoft’s electrode implant aims to reduce inflammation and scar tissue for patients, provide higher quality brain recordings for surgeons and neurologists, and potentially administer medication where needed most in the body. “Electrodes have been on the market for many years and are used for a lot of applications.
BioSpace
OCTOBER 20, 2021
Although California is already a well-known hotbed for science and technology, the pandemic still precipitated a surge of activity in the life sciences industry.
Advertisement
When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.
Pharma Times
OCTOBER 20, 2021
Lucid-PSYCH is a psychoactive compound potentially viable for the treatment of major depressive disorders
BioSpace
OCTOBER 20, 2021
Saama Technologies secured a $430 million investment from the Carlyle Group and venture funds from some of the pharmaceutical industry’s biggest companies.
Scienmag
OCTOBER 20, 2021
NEW YORK, October 20, 2021 — A multi-institutional research team has designed nanoparticles that can communicate with and slow the development of cancer cells. The work — detailed in a newly published paper in Advanced Materials — has uncovered a novel framework for the potential development of drug-free cancer therapies. Credit: Richard Huang and Ye […].
pharmaphorum
OCTOBER 20, 2021
A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients. The trial – which will be supported by pharma company Eisai and Ionian University in the US – will see if the test can identify people who have mild cognitive impairment (MCI) due to Alzheimer’s disease.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Scienmag
OCTOBER 20, 2021
New images have revealed detailed clues about how the first stars and structures were formed in the Universe and suggest the formation of the Galaxy got off to a fitful start. Credit: SHARDS research team New images have revealed detailed clues about how the first stars and structures were formed in the Universe and suggest the formation of the Galaxy got off to a fitful start.
Drug Patent Watch
OCTOBER 20, 2021
DrugPatentWatch has been ranked the “Best Biopharmaceuticals Commercial Business Intelligence Platform” by Global Health & Pharma News This award is dedicated to honoring the innovation, determination and outstanding levels of…. The post DrugPatentWatch Ranked Best Biopharmaceuticals Commercial Business Intelligence Platform appeared first on DrugPatentWatch - Make Better Decisions.
Scienmag
OCTOBER 20, 2021
The University of Massachusetts Amherst will be one of two sites for a national study that aims to better understand language and cognition in two groups of children affected by language disorders. Credit: UMass Amherst The University of Massachusetts Amherst will be one of two sites for a national study that aims to better understand […].
pharmaphorum
OCTOBER 20, 2021
An artificial intelligence-based tool for identifying hard-to-detect spinal fractures, developed by Belgian drugmaker UCB, has been licensed out to ImageBiopsy Lab for further development. The digital health tool, known as BoneBot, applies machine learning to X-rays to detect ‘silent’ or asymptomatic fractures in the vertebrae of the spine, a feature of the bone-wasting disease osteoporosis that can remain undiagnosed in more than two-thirds of cases.
Advertisement
As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.
Scienmag
OCTOBER 20, 2021
During the dinosaur era, a crab wandering near a coastal forest was buried alive in tree resin and became fossilized. 100 million years later, Javier Luque, a former predoctoral fellow at the Smithsonian Tropical Research Institute and currently a Research Associate at Harvard University, became aware of the crustacean trapped in amber thanks to Lida […].
Pharma Times
OCTOBER 20, 2021
ATDBio adds important platform solutions to Biotage within DNA and RNA oligonucleotide synthesis and purification
Scienmag
OCTOBER 20, 2021
While analyzing some of the world’s oldest coloured gemstones, researchers from the University of Waterloo discovered carbon residue that was once ancient life, encased in a 2.5 billion-year-old ruby. Credit: University of Waterloo While analyzing some of the world’s oldest coloured gemstones, researchers from the University of Waterloo discovered carbon residue that was once ancient […].
BioSpace
OCTOBER 20, 2021
ReCode is aiming to advance its lead candidates for cystic fibrosis and primary ciliary dyskinesia (PCD).
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Scienmag
OCTOBER 20, 2021
KENNEDY SPACE CENTER, FL. October 20,2021 – The International Space Station (ISS) National Laboratory has unveiled a research announcement seeking proposals to demonstrate biomanufacturing activities in microgravity. Targeted fields such as tissue engineering and biomanufacturing provide use cases for how ISS National Lab-sponsored research may lead to new biological products and tools that benefit humankind and […].
NY Times
OCTOBER 20, 2021
Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
Scienmag
OCTOBER 20, 2021
Looking at the ancient piece of amber, Javier Luque’s first thought wasn’t whether the crustacean trapped inside could help fill a crucial gap in crab evolution. He just, more or less, wondered what the heck is a crab doing stuck in fossilized tree resin? Credit: Artwork by Franz Anthony, courtesy of Javier Luque (Harvard University). […].
BioSpace
OCTOBER 20, 2021
Depression is the first indication, but other neurological conditions are being planned.
Advertisement
The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.
Expert insights. Personalized for you.
257 
Let's personalize your content